Ozempic vs Krispy Kreme: Wall Street firm bets weight-loss drugs won’t beat doughnut sales
Banking And Finance,Stock Market,Wall Street,Ozempic,Food,Public Health,Prescription Drugs
From the Right
AllSides Media Bias Rating: Lean Right
While the demand for weight loss drugs continues to surge, one Wall Street firm is betting that Americans' love for doughnuts is too strong to give them up.
Truist Securities on Monday upgraded Krispy Kreme to buy from hold, with analysts led by Bill Chappell saying that the negative impact of the glucagon-like peptide 1 (GLP-1) drugs has already been reflected in the stock's current valuation.
Check for Bias
The AI-powered AllSides Bias Checker instantly reveals the bias of a news article. Tap the button to use.
Related Coverage
.webp)
AllSides Picks
.webp)
Headline Roundup
Trump Admin Halts Over $1B in Medicaid Funding to CA, MN
July 22nd, 2026
Red Blue Translator
Great Depression (The)
Headline Roundup
Pentagon Updates Iran Casualty Numbers, Splits Post-July 7 Toll Into New Category
July 27th, 2026
News
Tracking Trump’s Campaign Promises
AllSides Staff
July 24th, 2026
